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for Patients With Severe Aortic Stenosis?*
Ron Waksman, MD, Augusto D. Pichard, MD“Man must be prepared for every event of life,
for there is nothing that is durable.”
—Menander (1)SEE PAGE 113U ntil recently, the standard of care for pa-tients with severe aortic stenosis (SAS) wassurgical aortic valve replacement (SAVR).
There is no doubt that SAVR outcomes have been
extremely good across broad populations and have
resulted in excellent procedural outcomes, including
low complication rates and acceptable durability of
the valve.
Transcatheter aortic valve replacement (TAVR)
was introduced >14 years ago and has since been
a continuation of technology iteration and improve-
ment, patient selection, and implantation techniques
(2). Today, with >125,000 procedures performed
in 750 global centers and a substantial amount of
emerging data, TAVR is challenging the exclusivity of
SAVR for the treatment of patients with SAS. Initially,
the efﬁcacy and safety of TAVR were demonstrated in
inoperable patients, also known as those at extreme
risk for surgery. For this population, TAVR produced
reductions in overall mortality (compared with med-
ical therapy or balloon valvuloplasty) with both
balloon-expandable and self-expanding valves (3,4).
As a result of these studies, the U.S. Food and Drug
Administration granted approval for the marketing of
TAVR, and it has become the standard of care in*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.patients who are at extreme risk for surgery. To
become a mainstream therapy for patients with aortic
stenosis, 2 important questions need to be addressed:
1) will TAVR be noninferior to surgery for the lower
risk population? and 2) will the durability of TAVR
match SAVR?
The next step was to examine the performance of
TAVR versus SAVR among patients at increased risk
for surgery. Both balloon-expandable and self-
expanding TAVR demonstrated noninferiority to
surgery for this patient population (5). Interestingly,
the self-expanding valve also showed superiority in
survival by an absolute 4.9 percentage points over
surgery (6). These results were received with excite-
ment, surprise, and some skepticism because there
were a few missing endpoints in the TAVR group, and
superiority would not have been established had the
conventional 1-sided alpha level of 0.025 been used
(7). In addition, there were other trial conduct issues
that introduced selection bias and potentially con-
founded the analysis.In this issue of the Journal, Reardon et al. (8) pre-
sent the 2-year results of the study and show not only
persistence of the 1-year results but also an increase
in the reduction from 4.9 to 6.5 percentage points
in mortality in favor of the self-expanding valve
compared with the surgical arm. Thus, the reduction
in overall mortality, which was of uncertain signiﬁ-
cance in the 1-year data, is now conﬁrmed with a
p value of 0.04. Similar continued divergence
was seen in the stroke rates of 6.5% at 1 year to
8.9% at 2 years. The question is whether the differ-
ences between years 1 and 2 are statistically signi-
ﬁcant. A landmark analysis could support whether
there is a continuation of improvement in the
long-term outcome in the TAVR group. There are
several questions that arise from this paper. 1) What
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expanding valve for mortality reduction and for the
improvement from the ﬁrst to the second year? 2) Are
these results consistent regardless of the access site
(transfemoral vs. transaortic)? 3) Are these results
speciﬁc to self-expanding valves, or can they be
generalized as a class effect for balloon-expandable
valves? We address these 3 points in the following
discussion.
Reardon et al. (8) suggest that higher rates of
bleeding, transfusion, acute kidney injury at the time
of surgery, and higher atrial ﬁbrillation rates in pa-
tients treated with surgery may worsen long-term
valve performance and can explain the superiority of
TAVR over SAVR. Although these arguments are
appealing, they are not entirely supported by pub-
lished reports. For example, hemodynamic differ-
ences, such as those presented in the study, are
clinically meaningless. In the PARTNER (Placement of
Aortic Transcatheter Valve) trial, aortic valve area
or gradients post-procedure did not affect clinical
outcome, although they were statistically better in the
TAVR group. In contrast, paravalvular regurgitation
post-TAVR, an established predictor for mortality (9),
was higher in the TAVR group in the self-expanding
study (6.1% vs. 0.6% moderate to severe, or 36% vs.
7.8% mild, moderate, and severe); however, it did not
inﬂuence mortality in the present study. Although
the data show that paravalvular leaks decrease with
time after self-expanding valves, we look forward to
the authors publishing the analysis for all-cause
mortality stratiﬁed according to paravalvular regur-
gitation at discharge. In addition, the high pacemaker
rates and vascular complications (which were also
higher in the TAVR group) cannot support improve-
ment in the mortality or stroke rates over 2 years of
follow-up. Therefore, the mechanism for superiority
of TAVR over SAVR in this analysis remains uncertain.
Because approximately 17% of the cases in the
TAVR arm were performed via a noniliofemoral ap-
proach (8), the statements of superiority should be
carefully reviewed for the TAVR alternative access. In
PARTNER 1A, when nearly 30% of the patients were
assigned to the transapical approach, SAVR was su-
perior to the transapical access with the balloon-
expandable valve for the primary endpoint of the
study. The use of alternative access is gradually
decreasing with the introduction of low-proﬁle TAVR
devices. The evidence for noninferiority of TAVR via
alternative access to conventional SAVR is lacking, as
are data for the optimal alternative access (e.g.,
transapical, transaortic, subclavian).
Although Reardon et al. (8) present data limited to
the self-expanding valve versus surgery, it does raisethe questions of whether these results can be viewed
as a class effect and whether they also apply to the
balloon-expandable valves. In the PARTNER trial, the
patients at high risk for surgery were randomized to
receive balloon-expandable valves, and an early
beneﬁt of these valves over surgery was found. This
survival beneﬁt, however, was lost early, and be-
tween 1 and 2 years, the survival curves were similar.
Nevertheless, comparing valves across different
studies would not be appropriate because of the dif-
ferences in certain factors, including the study pop-
ulation proﬁle and choice of access. To support the
class effect argument, a recent analysis comparing
balloon-expandable valves versus SAVR found that
for the patients with no or trace paravalvular regur-
gitation, there was a reduction in mortality in the
balloon-expandable valves with transfemoral access
compared with SAVR over a 5-year follow-up (45.2%
vs. 60.9%), emphasizing the need to eliminate para-
valvular regurgitation post-procedure (10). However,
not all valves are equal, and to support a class effect,
it would require a well-powered randomized trial
either comparing the valves head-to-head or against
surgery.
Clearly, there are identiﬁed populations that are
doing better with TAVR versus SAVR. In the PART-
NER studies, female sex, patients with smaller
annular size, and patients with low-ﬂow low gradient
had better outcomes with TAVR. In the present study
(8), patients who were <85 years of age, had a Society
of Thoracic Surgeons score #7%, and those with
normal left ventricular function, without hyperten-
sion, had a better survival if they underwent TAVR
compared with SAVR. This ﬁnding is promising and
may hint at what we should expect with the results
of TAVR versus SAVR in the intermediate-risk pop-
ulations. If this trend continues and durability of
the valve equates with surgery, it will afﬁrm TAVR
as the preferred intervention for younger and
healthier patients with aortic stenosis. Even if TAVR
is noninferior only to SAVR, it would be sufﬁcient
to have TAVR as the default strategy for patients
with SAS.
The most important question is whether TAVR
should become the default therapy for patients with
SAS who are at an increased surgical risk and beyond,
depending on the durability of the valve. The 2-year
data from the study by Reardon et al. (8) are a
strong signal to support this approach for the patient
with increased surgical risk. The patient’s choice is
for the less invasive option, early ambulation, fewer
complications, improved quality of life, and durable
outcome. The totality of the 5-year data with balloon-
expandable valves is sparse because of the advanced
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the studies. Thus far, the signals are encouraging
regarding the functionality of the valve for those
who reached the 5-year follow-up and beyond (11).
The present study and others conﬁrm that the
intermediate-term results are encouraging regarding
the functional performance of TAVR compared with
surgery in the high-risk population.
Looking forward, the message is clear: TAVR via
femoral access should be considered as the ﬁrst-line
therapy for patients with SAS who are at an
increased risk for surgery. SAVR should be considered
only for patients who are not suitable for TAVR or
when the data are not available yet (intermediate-
and low-risk PARTNER 2A and SURTAVI [Surgical
Replacement and Transcatheter Aortic Valve Im-
plantation]). Published reports have already noted
the noninferior results of TAVR versus SAVR for lower
risk populations (12). The majority of surgeons arecurrently embracing TAVR and converting SAVR
cases to TAVR as part of the heart team approach,
making the possibility that TAVR will become main-
stream therapy a reality (13).
With the rapid accumulation of data, it is time for
the societies to update and upgrade their guidelines
and equate them to the surgery guidelines for the
high-risk patient population (14). Insurers should also
recognize the totality of the evidence that supports
TAVR and upgrade reimbursements to be in syn-
chronization with labeling by the U.S. Food and Drug
Administration. Cost should not be an obstacle or
prohibit patients with SAS from having the best
evidence-based medicine therapy available.
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